VivoSim Labs (VIVS) Depreciation & Amortization (CF) (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Depreciation & Amortization (CF) of $43000.0 for Q1 2026, down 29.51% year-over-year from $61000.0 in Q1 2025, and down 17.31% quarter-over-quarter from $52000.0 in Q4 2025.
VivoSim Labs (VIVS) Depreciation & Amortization (CF) (2011 - 2026) Analysis & Trends
VivoSim Labs' Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $43000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 29.51% year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $215000.0 (down 19.17% YoY), while the FY2026 annual figure was $215000.0, down 19.17% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $43000.0, down from $52000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $130000.0 in Q4 2022, with the low at $43000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $61000.0 (2025), against an average of $64705.9.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) jumped 251.35% in 2022, then plunged 45.38% in 2023.
- VivoSim Labs' Depreciation & Amortization (CF) stood at $130000.0 in 2022, then slumped by 45.38% to $71000.0 in 2023, then slipped by 5.63% to $67000.0 in 2024, then dropped by 22.39% to $52000.0 in 2025, then fell by 17.31% to $43000.0 in 2026.
- Business Quant data shows VIVS's Depreciation & Amortization (CF) at $43000.0 in Q1 2026, $52000.0 in Q4 2025, and $59000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40,000.00 |
| Jun 30, 2026 | 40,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 71,000.00 |
| Mar 31, 2024 | 71,000.00 |